NCT05654883
New York City Observational Study of Mpox Immunity
Enrolling by Invitation
Not specifiedAges 18+ObservationalNYU Langone HealthInvestigator-initiated
~174 participants
Updated 2025-10-30 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Geometric Mean Titer (GMT) of Serum Neutralization of Mpox Virus approximately 14 Days After Second Vaccination
Measured over Day 14 Post-Second Vaccination
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesNew York1
Study leadership
- Angelica Kottkamp, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Geometric Mean Titer (GMT) of Serum Neutralization of Mpox Virus approximately 14 Days After Second VaccinationDay 14 Post-Second Vaccination
Measured using live-virus mpox neutralization assay, plaque reduction neutralization assay (PRNT).
- Number of Solicited Adverse Events through Day 14 Post-VaccinationsDay 14 Post-Vaccination
Participants will complete a 14-day diary recording solicited adverse events following each vaccination.
- Number of Adverse Events that Occur within 28 Days After Final VaccinationDay 28 Post-Final Vaccination